Appendix 2—table 6. Unadjusted COVID-19-Related Outcomes Stratified by Age, Sex, & Age by Sex; Matched Primary Analysis Cohort, All-Regions Combined.
| Primary Analysis Cohort, All Regions Matched | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All | SARS-CoV-2 Test | COVID-19 Diagnosis | COVID-19 Hospitalization | ||||||||||||||
| N | % | N | % | OR | p-value | N | % | OR | p-value | N | % | OR | p-value | ||||
| LL | UL | LL | UL | LL | UL | ||||||||||||
| All Patients | 900,732 | 100.0% | 28,137 | 3.1% | 16,289 | 1.8% | 3,710 | 0.4% | |||||||||
| BP User | 450,366 | 50.0% | 5,189 | 1.2% | 0.22 | <0.001 | 3,024 | 0.7% | 0.22 | <0.001 | 715 | 0.2% | 0.24 | <0.001 | |||
| BP Non-user | 450,366 | 50.0% | 22,948 | 5.1% | 0.21 | 0.22 | 13,265 | 2.9% | 0.21 | 0.23 | 2,995 | 0.7% | 0.22 | 0.26 | |||
| By Age | |||||||||||||||||
| Age ≤20 | 2,253 | 100.0% | 67 | 3.0% | 14 | 0.6% | 2 | 0.1% | |||||||||
| BP User | 1,128 | 50.1% | 29 | 2.6% | 0.75 | 0.26 | 2 | 0.2% | 0.16 | 0.007 | 2 | 0.2% | NA | NA | |||
| BP Non-user | 1,125 | 49.9% | 38 | 3.4% | 0.46 | 1.23 | 12 | 1.1% | 0.04 | 0.74 | 0 | 0.0% | NA | NA | |||
| Age 21-40 | 6,195 | 100.0% | 335 | 5.4% | 115 | 1.9% | 13 | 0.2% | |||||||||
| BP User | 3,091 | 49.9% | 58 | 1.9% | 0.20 | <0.001 | 15 | 0.5% | 0.15 | <0.001 | 4 | 0.1% | 0.45 | 0.27 | |||
| BP Non-user | 3,104 | 50.1% | 277 | 8.9% | 0.15 | 0.26 | 100 | 3.2% | 0.08 | 0.25 | 9 | 0.3% | 0.14 | 1.45 | |||
| Age 41-50 | 17,096 | 100.0% | 894 | 5.2% | 270 | 1.6% | 54 | 0.3% | |||||||||
| BP User | 8,551 | 50.0% | 188 | 2.2% | 0.25 | <0.001 | 48 | 0.6% | 0.21 | <0.001 | 14 | 0.2% | 0.35 | <0.001 | |||
| BP Non-user | 8,545 | 50.0% | 706 | 8.3% | 0.21 | 0.29 | 222 | 2.6% | 0.15 | 0.29 | 40 | 0.5% | 0.19 | 0.64 | |||
| Age 51-60 | 131,445 | 100.0% | 5,765 | 4.4% | 2,371 | 1.8% | 397 | 0.3% | |||||||||
| BP User | 65,721 | 50.0% | 1,104 | 1.7% | 0.22 | <0.001 | 456 | 0.7% | 0.23 | <0.001 | 83 | 0.1% | 0.26 | <0.001 | |||
| BP Non-user | 65,724 | 50.0% | 4,661 | 7.1% | 0.21 | 0.24 | 1,915 | 2.9% | 0.21 | 0.26 | 314 | 0.5% | 0.21 | 0.34 | |||
| Age 61-70 | 313,822 | 100.0% | 10,438 | 3.3% | 5,029 | 1.6% | 1,035 | 0.3% | |||||||||
| BP User | 156,878 | 50.0% | 1,843 | 1.2% | 0.21 | <0.001 | 939 | 0.6% | 0.23 | <0.001 | 173 | 0.1% | 0.20 | <0.001 | |||
| BP Non-user | 156,944 | 50.0% | 8,595 | 5.5% | 0.20 | 0.22 | 4,090 | 2.6% | 0.21 | 0.24 | 862 | 0.5% | 0.17 | 0.24 | |||
| Age 71-80 | 280,803 | 100.0% | 7,179 | 2.6% | 4,827 | 1.7% | 1,212 | 0.4% | |||||||||
| BP User | 140,437 | 50.0% | 1,309 | 0.9% | 0.22 | <0.001 | 877 | 0.6% | 0.22 | <0.001 | 234 | 0.2% | 0.24 | <0.001 | |||
| BP Non-user | 140,366 | 50.0% | 5,870 | 4.2% | 0.20 | 0.23 | 3,950 | 2.8% | 0.20 | 0.23 | 978 | 0.7% | 0.21 | 0.27 | |||
| Age ≥81 | 149,118 | 100.0% | 3,459 | 2.3% | 3,663 | 2.5% | 997 | 0.7% | |||||||||
| BP User | 74,560 | 50.0% | 658 | 0.9% | 0.23 | <0.001 | 687 | 0.9% | 0.22 | <0.001 | 205 | 0.3% | 0.26 | <0.001 | |||
| BP Non-user | 74,558 | 50.0% | 2,801 | 3.8% | 0.21 | 0.25 | 2,976 | 4.0% | 0.21 | 0.24 | 792 | 1.1% | 0.22 | 0.30 | |||
| Female Patients | 811,497 | 100.0% | 24,936 | 3.1% | 14,367 | 1.8% | 3,127 | 0.4% | |||||||||
| BP User | 405,751 | 50.0% | 4,519 | 1.1% | 0.21 | <0.001 | 2,667 | 0.7% | 0.22 | <0.001 | 593 | 0.1% | 0.23 | <0.001 | |||
| BP Non-user | 405,746 | 50.0% | 20,417 | 5.0% | 0.21 | 0.22 | 11,700 | 2.9% | 0.21 | 0.23 | 2,534 | 0.6% | 0.21 | 0.25 | |||
| By Age | |||||||||||||||||
| Age ≤20 | 885 | 100.0% | 26 | 2.9% | 7 | 0.8% | 1 | 0.1% | |||||||||
| BP User | 442 | 49.9% | 11 | 2.5% | 0.73 | 0.43 | 1 | 0.2% | 0.17 | 0.12 | 1 | 0.2% | NA | NA | |||
| BP Non-user | 443 | 50.1% | 15 | 3.4% | 0.33 | 1.60 | 6 | 1.4% | 0.02 | 1.38 | 0 | 0.0% | NA | NA | |||
| Age 21-40 | 3,765 | 100.0% | 218 | 5.8% | 64 | 1.7% | 9 | 0.2% | |||||||||
| BP User | 1,879 | 49.9% | 40 | 2.1% | 0.21 | <0.001 | 12 | 0.6% | 0.23 | <0.001 | 3 | 0.2% | 0.50 | 0.51 | |||
| BP Non-user | 1,886 | 50.1% | 178 | 9.4% | 0.15 | 0.30 | 52 | 2.8% | 0.12 | 0.43 | 6 | 0.3% | 0.13 | 2.01 | |||
| Age 41-50 | 13,542 | 100.0% | 730 | 5.4% | 206 | 1.5% | 37 | 0.3% | |||||||||
| BP User | 6,774 | 50.0% | 157 | 2.3% | 0.26 | <0.001 | 43 | 0.6% | 0.26 | <0.001 | 11 | 0.2% | 0.42 | 0.01 | |||
| BP Non-user | 6,768 | 50.0% | 573 | 8.5% | 0.21 | 0.31 | 163 | 2.4% | 0.18 | 0.36 | 26 | 0.4% | 0.21 | 0.85 | |||
| Age 51-60 | 119,205 | 100.0% | 5,200 | 4.4% | 2,093 | 1.8% | 327 | 0.3% | |||||||||
| BP User | 59,602 | 50.0% | 973 | 1.6% | 0.22 | <0.001 | 399 | 0.7% | 0.23 | <0.001 | 64 | 0.1% | 0.24 | <0.001 | |||
| BP Non-user | 59,603 | 50.0% | 4,227 | 7.1% | 0.20 | 0.23 | 1,694 | 2.8% | 0.21 | 0.26 | 263 | 0.4% | 0.18 | 0.32 | |||
| Age 61-70 | 290,276 | 100.0% | 9,474 | 3.3% | 4,506 | 1.6% | 885 | 0.3% | |||||||||
| BP User | 145,131 | 50.0% | 1,639 | 1.1% | 0.20 | <0.001 | 851 | 0.6% | 0.23 | <0.001 | 144 | 0.1% | 0.19 | <0.001 | |||
| BP Non-user | 145,145 | 50.0% | 7,835 | 5.4% | 0.19 | 0.21 | 3,655 | 2.5% | 0.21 | 0.25 | 741 | 0.5% | 0.16 | 0.23 | |||
| Age 71-80 | 253,094 | 100.0% | 6,304 | 2.5% | 4,254 | 1.7% | 1,026 | 0.4% | |||||||||
| BP User | 126,559 | 50.0% | 1,140 | 0.9% | 0.21 | <0.001 | 769 | 0.6% | 0.22 | <0.001 | 193 | 0.2% | 0.23 | <0.001 | |||
| BP Non-user | 126,535 | 50.0% | 5,164 | 4.1% | 0.20 | 0.23 | 3,485 | 2.8% | 0.20 | 0.23 | 833 | 0.7% | 0.20 | 0.27 | |||
| Age ≥81 | 130,730 | 100.0% | 2,984 | 2.3% | 3,237 | 2.5% | 842 | 0.6% | |||||||||
| BP User | 65,364 | 50.0% | 559 | 0.9% | 0.22 | <0.001 | 592 | 0.9% | 0.22 | <0.001 | 177 | 0.3% | 0.26 | <0.001 | |||
| BP Non-user | 65,366 | 50.0% | 2,425 | 3.7% | 0.20 | 0.25 | 2,645 | 4.0% | 0.20 | 0.24 | 665 | 1.0% | 0.22 | 0.31 | |||
| Male Patients | 89,235 | 100.0% | 3,201 | 3.6% | 1,922 | 2.2% | 583 | 0.7% | |||||||||
| BP User | 44,615 | 50.0% | 670 | 1.5% | 0.25 | <0.001 | 357 | 0.8% | 0.22 | <0.001 | 122 | 0.3% | 0.26 | <0.001 | |||
| BP Non-user | 44,620 | 50.0% | 2,531 | 5.7% | 0.23 | 0.28 | 1,565 | 3.5% | 0.20 | 0.25 | 461 | 1.0% | 0.22 | 0.32 | |||
| By Age | |||||||||||||||||
| Age ≤20 | 1,368 | 100.0% | 41 | 3.0% | 7 | 0.5% | 1 | 0.1% | |||||||||
| BP User | 686 | 50.1% | 18 | 2.6% | 0.77 | 0.42 | 1 | 0.1% | 0.16 | 0.07 | 1 | 0.1% | NA | NA | |||
| BP Non-user | 682 | 49.9% | 23 | 3.4% | 0.41 | 1.44 | 6 | 0.9% | 0.02 | 1.37 | 0 | 0.0% | NA | NA | |||
| Age 21-40 | 2,430 | 100.0% | 117 | 4.8% | 51 | 2.1% | 4 | 0.2% | |||||||||
| BP User | 1,212 | 49.9% | 18 | 1.5% | 0.17 | <0.001 | 3 | 0.2% | 0.06 | <0.001 | 1 | 0.1% | 0.33 | 0.63 | |||
| BP Non-user | 1,218 | 50.1% | 99 | 8.1% | 0.10 | 0.28 | 48 | 3.9% | 0.02 | 0.19 | 3 | 0.2% | 0.03 | 3.22 | |||
| Age 41-50 | 3,554 | 100.0% | 164 | 4.6% | 64 | 1.8% | 17 | 0.5% | |||||||||
| BP User | 1,777 | 50.0% | 31 | 1.7% | 0.22 | <0.001 | 5 | 0.3% | 0.08 | <0.001 | 3 | 0.2% | 0.21 | 0.01 | |||
| BP Non-user | 1,777 | 50.0% | 133 | 7.5% | 0.15 | 0.33 | 59 | 3.3% | 0.03 | 0.21 | 14 | 0.8% | 0.06 | 0.74 | |||
| Age 51-60 | 12,240 | 100.0% | 565 | 4.6% | 278 | 2.3% | 70 | 0.6% | |||||||||
| BP User | 6,119 | 50.0% | 131 | 2.1% | 0.29 | <0.001 | 57 | 0.9% | 0.25 | <0.001 | 19 | 0.3% | 0.37 | <0.001 | |||
| BP Non-user | 6,121 | 50.0% | 434 | 7.1% | 0.24 | 0.35 | 221 | 3.6% | 0.19 | 0.34 | 51 | 0.8% | 0.22 | 0.63 | |||
| Age 61-70 | 23,546 | 100.0% | 964 | 4.1% | 523 | 2.2% | 150 | 0.6% | |||||||||
| BP User | 11,747 | 49.9% | 204 | 1.7% | 0.26 | <0.001 | 88 | 0.7% | 0.20 | <0.001 | 29 | 0.2% | 0.24 | <0.001 | |||
| BP Non-user | 11,799 | 50.1% | 760 | 6.4% | 0.22 | 0.30 | 435 | 3.7% | 0.16 | 0.25 | 121 | 1.0% | 0.16 | 0.36 | |||
| Age 71-80 | 27,709 | 100.0% | 875 | 3.2% | 573 | 2.1% | 186 | 0.7% | |||||||||
| BP User | 13,878 | 50.1% | 169 | 1.2% | 0.23 | <0.001 | 108 | 0.8% | 0.23 | <0.001 | 41 | 0.3% | 0.28 | <0.001 | |||
| BP Non-user | 13,831 | 49.9% | 706 | 5.1% | 0.19 | 0.27 | 465 | 3.4% | 0.18 | 0.28 | 145 | 1.0% | 0.20 | 0.40 | |||
| Age ≥81 | 18,388 | 100.0% | 475 | 2.6% | 426 | 2.3% | 155 | 0.8% | |||||||||
| BP User | 9,196 | 50.0% | 99 | 1.1% | 0.26 | <0.001 | 95 | 1.0% | 0.28 | <0.001 | 28 | 0.3% | 0.22 | <0.001 | |||
| BP Non-user | 9,192 | 50.0% | 376 | 4.1% | 0.20 | 0.32 | 331 | 3.6% | 0.22 | 0.35 | 127 | 1.4% | 0.14 | 0.33 | |||
BP: bisphosphonate; LL: lower 95% confidence interval level; NA: not applicable; OR: odds ratio; UL: upper 95% confidence interval level.